Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, Goubet AG, Leduc M, Chen N, Tan TZ, Signolle N, Bigorgne A, Dussiot M, Tselikas L, Susini S, Danlos FX, Schneider AK, Chabanon R, Vacher S, Bièche I, Lebret T, Allory Y, Soria JC, Arpaia N, Kroemer G, Kepp O, Thiery JP, Zitvogel L, Marabelle A. Rouanne M, et al. Among authors: tselikas l. J Clin Invest. 2022 Jun 15;132(12):e145666. doi: 10.1172/JCI145666. J Clin Invest. 2022. PMID: 35503263 Free PMC article.
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study.
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Gregory J, et al. Among authors: tselikas l. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):921-928. doi: 10.1007/s00259-022-06002-5. Epub 2022 Oct 25. Eur J Nucl Med Mol Imaging. 2023. PMID: 36282299 Review.
Basic Knowledge in Soft Tissue Sarcoma.
Bourcier K, Le Cesne A, Tselikas L, Adam J, Mir O, Honore C, de Baere T. Bourcier K, et al. Among authors: tselikas l. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1255-1261. doi: 10.1007/s00270-019-02259-w. Epub 2019 Jun 24. Cardiovasc Intervent Radiol. 2019. PMID: 31236647 Review.
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D. Facchinetti F, et al. Among authors: tselikas l. Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6. Eur J Cancer. 2020. PMID: 32388065
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Sarkozy C, Michot JM, Quivoron C, Camara-Clayette V, Danu A, Lazarovici J, El-Dakdouki Y, Saleh K, Ghez D, Rossignol J, Baldini C, Arfi-Rouche J, Romano-Martin P, Tselikas L, Varga A, Gazzah A, Hollebecque A, Lacroix L, Bahleda R, Lecourt H, Vergé V, Rahali W, Cotteret S, Soria JC, Dartigues P, Massard C, Ribrag V. Sarkozy C, et al. Among authors: tselikas l. Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10. Am J Hematol. 2021. PMID: 34165816 Free article. Clinical Trial. No abstract available.
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.
Tselikas L, Dardenne A, de Baere T, Faron M, Ammari S, Farhane S, Suzzoni S, Danlos FX, Raoult T, Susini S, Al Shatti N, Mouraud S, Deschamps F, Kobe A, Delpla A, Roux C, Baldini C, Soria JC, Barlesi F, Massard C, Robert C, Champiat S, Marabelle A. Tselikas L, et al. Eur J Cancer. 2022 Sep;172:1-12. doi: 10.1016/j.ejca.2022.05.024. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35724442
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers.
Bredel D, Tihic E, Mouraud S, Danlos FX, Susini S, Aglave M, Alfaro A, Mohamed-Djalim C, Rouanne M, Halse H, Bigorgne A, Tselikas L, Dalle S, Hartl DM, Baudin E, Guettier C, Vibert E, Rosmorduc O, Robert C, Ferlicot S, Parier B, Albiges L, de Montpreville VT, Besse B, Mercier O, Even C, Breuskin I, Classe M, Radulescu C, Lebret T, Pautier P, Gouy S, Scoazec JY, Zitvogel L, Marabelle A, Bonvalet M. Bredel D, et al. Among authors: tselikas l. J Exp Clin Cancer Res. 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6. J Exp Clin Cancer Res. 2023. PMID: 38057799 Free PMC article.
170 results